Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma

Hepatology International

Volumn 5, Issue 3, 2011, Pages 850-856

  Ogasawara, Sadahisa ^a   Kanai, Fumihiko ^a   Obi, Shuntaro ^b   Sato, Shinpei ^b   Yamaguchi, Taketo ^c   Azemoto, Ryosaku ^d   Mizumoto, Hideaki ^e   Koushima, Youhei ^f   Morimoto, Naoki ^g   Hirata, Nobuto ^h   Toriyabe, Takeshi ^a   Shinozaki, Yusuke ^a   Ooka, Yoshihiko ^a   Mikata, Rintaro ^a   Chiba, Tetsuhiro ^a   Okabe, Shinichiro ^a   Imazeki, Fumio ^a   Yoshikawa, Masaharu ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Kyoundo Hospital   (Japan)

^c CHIBA CANCER CENTER   (Japan)

^d KIMITSU CHUO HOSPITAL   (Japan)

^e Funabashi Municipal Medical Center   (Japan)

^f SAITAMA RED CROSS HOSPITAL   (Japan)

^g Shimotsuga General Hospital   (Japan)

^h Kameda Medical Centre   (Japan)

Author keywords

Hepatocellular carcinoma; Japanese; Safety; Sorafenib; Tolerance

Indexed keywords

SORAFENIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; ASCITES; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; JAPANESE; JAUNDICE; LIVER CELL CARCINOMA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT DURATION; VOICE CHANGE; VOMITING;

EID: 80055013740     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-010-9249-4     Document Type: Article

References (22)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108 (Pubitemid 40372904)
2. Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, Teratani T, Tohgo G, Toda N, Ohashi M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B-and C-viral infection in Japan. Part 1. Hepatology 1995;22(4):1027-1033
3. Okuda H. Hepatocellular carcinoma development in cirrhosis. Best Pract Res Clin Gastroenterol 2007;21(1):161-173 (Pubitemid 46075999)
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362(9399):1907-17 (Pubitemid 37518510)
5. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr. International trends and patterns of primary liver cancer. Int J Cancer 2001;94(2):290-296 (Pubitemid 32911426)
6. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007;37(Suppl 2):S95-S100
7. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340(10):745-750 (Pubitemid 29114292)
8. Ryu M, Shimamura Y, Kinoshita T, Konishi M, Kawano N, Iwasaki M, Furuse J, Yoshino M, Moriyama N, Sugita M. Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: A retrospective multicentre study. Jpn J Clin Oncol 1997;27(4):251-257 (Pubitemid 127516775)
9. Okuda K, Mitchell DG, Itai Y. In Hepatobiliary Disease Primary Malignant Tumors of the Liver. London: Blackwell; 2001. 343-389
10. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35(3):421-430 (Pubitemid 32844200)
11. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359(9319):1734-1739 (Pubitemid 34607087)
12. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131(2):461-469 (Pubitemid 44142456)
13. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-7109 (Pubitemid 39331023)
14. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-390
15. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 2009;10(1):25-34
16. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99(1):159-165 (Pubitemid 350239045)
17. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(26):4293-4300 (Pubitemid 46630787)
18. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009;24(3):346-353
19. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007;37(10):755-762 (Pubitemid 350120299)
20. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008;9(2):117-123
21. Ozenne V, Paradis V, Pernot S, Castelnau C, Vullierme MP, Bouattour M, Valla D, Farges O, Degos F. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2010;22(9):1106-1110
22. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Konigsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009;14(1):70-76